Orvar™ Autoantigen Discovery Technology

Orvar™ Autoantigen Discovery Technology

  • The Orvar™ Autoantigen Discovery Technology identifies all the autoantigens and antigens that make up the Autoproteome™ – the totality of autoantigens and antigens within a human at any one time the individual may or may not have the disease.
  • Once the Autoproteome™ is identified, the KREX™ technology is used to produce a custom protein array that serves as a validated, true positive antigen and autoantigen library which is disease-specific.

Orvar™ can be used to:

  • Discover autoantibodies for characterisation of diseases either as biomarkers for early diagnostics, protective autoantibodies or intra-disease stratification.

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics UK Ltd. Registered in England and Wales no. 12889389 | Sengenics Corporation Pte. Ltd. Registered in Singapore no. 201734100D